Separate indirect from direct design evidence (SIDDE)

Fixed effects model: 

                    comparison k  nma direct indir. RoR z p-value
 BZD-intermediate:daridorexant 0 2.33      .   2.33   . .       .
      BZD-intermediate:placebo 1 2.11   2.11      .   . .       .
  BZD-intermediate:seltorexant 0 3.12      .   3.12   . .       .
     BZD-intermediate:zolpidem 0 2.52      .   2.52   . .       .
          daridorexant:placebo 1 0.91   0.99      .   . .       .
      daridorexant:seltorexant 0 1.34      .   1.34   . .       .
         daridorexant:zolpidem 1 1.08   0.99      .   . .       .
           seltorexant:placebo 1 0.68   0.59      .   . .       .
              zolpidem:placebo 4 0.84   0.85      .   . .       .
          seltorexant:zolpidem 1 0.81   1.01      .   . .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
[1] "Percent of comparisons where there is some evidence (p-value<0.05) of disagreement between direct and indirect sources: NaN. (0 out of 0 comparisons)."
[1] "File created on 2022-06-08"
